Skip to main content
Premium Trial:

Request an Annual Quote

Where are they now?: Oct 1, 2002


In Genome Technology last October, our cover story looked at the changing image of Affymetrix and how the microarray heavyweight was hoping to keep its corner on the market. A year later, the company, which plans to stay in the expression business as it expands its reach into genotyping, has announced increases in sales over the past year. Revenues for 2002 have also been higher than expected. And it seems that the image campaign has been working: Affymetrix was chosen as the 2002 GT All-Star for Company of the Year, and both president Sue Siegel and CEO Stephen Fodor were nominated for the All-Stars as well (see p. 51). Siegel was a runner-up for Person of the Year, and Fodor won his category for Most Masterful in Microarrays.

Also in last year’s issue was our annual Freeloaders’ Guide to GSAC, which we included in the September issue this year because the conference was moved up to the beginning of October (perhaps in a nod to the frosty Boston climate?).

And in a strange coincidence, two completely separate articles in the October issue wound up very much linked a year later. One was a brief story on the use of sequencing technology and bioinformatics techniques to identify the badly decomposed and mutilated remains found in mass graves in Sarajevo. The other was our Wild Type, featuring Gene Codes’ president Howard Cash. By the time the October 2001 issue hit your desk, Cash’s company was working on new software to help identify and track the remains found at the World Trade Center site. Because of that work, which entailed launching Gene Codes Forensics and making countless trips to New York City, Cash was selected by voters as this year’s GT All-Star Person of the Year (see p. 68).


The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.